Cardiocel will be huge in time but all I can see is the vaccine platform going bezerk shortly.
Did you guys know GSK had two failed vaccine trials for Hsv. They spent 2.5 billion dollars. But they went very close to having a prophylactic vaccine for hsv-1. Using the same polynucleotide approach as Frazer is using. Without his two tricks, ubiquitin for a robust tcell response and codon modification for neutrelizing antibodies. Could be any day now.
Centres by end of year?, page-19
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
0.000(0.00%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $14.05 | $14.05 | $14.00 | $10.05K | 718 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 665 | $13.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 225 | 2 |
View Market Depth
| Last trade - 10.13am 08/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |